CD274 and hepatocellular carcinoma: Similarly, another phase II trial (NCT05750030) will evaluate the safety, feasibility, and efficacy of FMT from patients with HCC who responded to PD-L1-based immunotherapy to patients with HCC who failed to respond to atezolizumab/bevacizumab [74].